CHMP recommends Lymphoseek for radiopharmacutical diagnosis - Navidea Biopharmaceuticals
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lymphoseek, 250 �g, kit for radiopharmaceutical preparation, intended for diagnostic use only. The applicant for this medicinal product is Navidea Biopharmaceuticals Limited.
The active substance of Lymphoseek is tilmanocept, a diagnostic radiopharmaceutical (V09IA09) that specifically binds to mannose binding receptor proteins (CD206) that reside on the surface of macrophages and dendritic cells present in the tumour draining lymph nodes (sentinel lymph nodes).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.